Although AXL has been studied in thyroid‐related cancer, such as papillary thyroid carcinoma, as well as in fibrotic diseases, including pulmonary, hepatic, and intestinal fibrosis, its role in ocular biology remains unexplored.[58, 59, 60, 61] Currently, TP0903, a specific inhibitor of AXL,[62, 63] is in a phase II clinical trial for the treatment of acute myeloid leukemia (NCT03013998), with no direct evidence of application in any fibrotic diseases. Here, AXL is linked to differentiated thyroid carcinoma.